SCHEMBL632301

SCHEMBL632301

CC(C)Nc1ccccc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.49
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
TDP1 Q9NUW8 2/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
LMNA P02545 3/20 0.44
GAA P10253 1/20 0.44
PSIP1 O75475 1/20 0.44
IDO1 P14902 1/20 0.44
ALDH1A1 P00352 2/20 0.43
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
THRB P10828 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29133244 0.85 L3MBTL1 (0.45) L3MBTL1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL15742977 0.82 KMT2A (0.49) L3MBTL1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL17048148 0.82 TDP1 (0.38) L3MBTL1KMT2AMEN1TDP1MAPK1
SCHEMBL2962223 0.82 TDP1 (0.57) L3MBTL1KMT2AMEN1TDP1SMN1; SMN2
SCHEMBL14017790 0.80 GAA (0.45) L3MBTL1KMT2AMEN1TDP1MAPK1
SCHEMBL5720958 0.79 L3MBTL1 (0.44) L3MBTL1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL4131268 0.79 L3MBTL1 (0.44) L3MBTL1KMT2AMEN1MAPK1SMN1; SMN2
SCHEMBL21316930 0.79 TDP1 (0.35) L3MBTL1KMT2AMEN1TDP1MAPK1
SCHEMBL3634673 0.79 HDAC1 (0.42) L3MBTL1KMT2AMEN1TDP1MAPK1
SCHEMBL23114054 0.78 RAB9A (0.46) L3MBTL1KMT2AMEN1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919858-B2 Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2024-03-05 US disclosed
US-20230242565-A1 Macrolides with Modified Desosamine Sugars and Uses Thereof ZIKANI THERAPEUTICS, INC. 2023-08-03 US disclosed
US-20230242565-A1 Macrolides with Modified Desosamine Sugars and Uses Thereof ZIKANI THERAPEUTICS, INC. 2023-08-03 US disclosed
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
US-11673910-B2 Macrolides with modified desosamine sugars and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2023-06-13 US disclosed
US-11673910-B2 Macrolides with modified desosamine sugars and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2023-06-13 US disclosed
US-20200148643-A1 AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2020-05-14 US disclosed
US-20190330142-A1 INHIBITORS OF MTOR-DEPTOR INTERACTIONS AND METHODS OF USE THEREOF THE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2019-10-31 US disclosed
US-20080096906-A1 AMINOMETHYL-2-IMIDAZOLES HOFFMANN-LA ROCHE INC. 2008-04-24 US disclosed
WO-2008046756-A1 AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2008-04-24 WO disclosed
WO-2008046757-A1 AMINOMETHYL-4-IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-24 WO disclosed
US-7335677-B2 Inhibitors of dipeptidyl peptidase IV FERRING B.V. (NL) 2008-02-26 US disclosed
US-7335677-B2 Inhibitors of dipeptidyl peptidase IV FERRING B.V. (NL) 2008-02-26 US disclosed
US-20070191380-A1 KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION IRM LLC (BM) 2007-08-16 US disclosed
US-7176312-B2 Kinase inhibitor scaffolds and methods for their preparation THE SCRIPPS RESEARCH INSTITUTE (US) 2007-02-13 US disclosed
EP-0300344-B1 HALOGENATED THIADIAZOLYLOXYACETIC ACID AMIDES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES BAYER AG (DE) 1993-10-06 EP disclosed
EP-0334332-A1 Ortho-alkylated aromatic amines via gamma alumina catalyst AIR PRODUCTS AND CHEMICALS, INC. (US) 1989-09-27 EP disclosed
EP-0300344-A1 Halogenated thiadiazolyloxyacetic acid amides, process and intermediates for their preparation and their use as herbicides BAYER AG (DE) 1989-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673910-B2 Macrolides with modified desosamine sugars and uses thereof FUT6, DDOST, MGAM L3MBTL1 1154/4885KMT2A 1230/4885MEN1 3379/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR L3MBTL1 2256/4885KMT2A 3974/4885MEN1 1948/4885
US-20200148643-A1 AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES UBQLN1, UBQLN2, PSMB1 L3MBTL1 2557/4885KMT2A 1444/4885MEN1 2842/4885
US-20080096906-A1 AMINOMETHYL-2-IMIDAZOLES HTR2C, AHR, HAX1 L3MBTL1 3083/4885KMT2A 98/4885MEN1 1551/4885
US-20230219927-A1 AKT3 MODULATORS AKT3, AKT2, PIK3CA L3MBTL1 3768/4885KMT2A 4131/4885MEN1 1172/4885
US-20070191380-A1 KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION MAP2K2, MAP2K1, MAP2K7 L3MBTL1 2431/4885KMT2A 580/4885MEN1 1815/4885
US-20230242565-A1 Macrolides with Modified Desosamine Sugars and Uses Thereof FUT6, DDOST, MGAM L3MBTL1 1154/4885KMT2A 1230/4885MEN1 3379/4885
US-11919858-B2 Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases UBQLN1, PSMB1, UBQLN2 L3MBTL1 2726/4885KMT2A 1688/4885MEN1 2805/4885
US-20190330142-A1 INHIBITORS OF MTOR-DEPTOR INTERACTIONS AND METHODS OF USE THEREOF DEPTOR, RICTOR, RPTOR L3MBTL1 3113/4885KMT2A 1661/4885MEN1 1433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.